Report

FDA Requires New Vision Loss Warnings for Ozempic, Wegovy and Other GLP-1s Over NAION Risk

Report from the mass tort press

Headline as published by AboutLawsuits.com on Nov 9, 2026; collected by the wire Nov 9, 2026, 5:01 PM ET.

Read at AboutLawsuits.com

Coverage

  1. AboutLawsuits.com Mass tort press

    FDA Requires New Vision Loss Warnings for Ozempic, Wegovy and Other GLP-1s Over NAION Risk

Named in this story

Topics

Explore the named firms, organizations and MDL dockets above. Sources and method

MDL No. 3163

GLP-1 Vision Loss (NAION)

IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation

Transferee judge
Karen S. Marston
Court
Eastern District of Pennsylvania
Actions pending
247

Per the JPML pending-dockets report of October 1, 2026.